Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Neurological Sciences
Published in: Neurological Sciences 3/2021

01-03-2021 | Underweight | Original Article

Prevalence, risk factors, and clinical correlations of underweight in Chinese newly diagnosed and drug-naïve patients with Parkinson’s disease

Authors: Qing Wu, Ming Yu, Jianfei Fu, Meizhen Liu

Published in: Neurological Sciences | Issue 3/2021

Login to get access

Abstract

Objective

Studies have shown that patients with Parkinson’s disease (PD) will experience weight loss during the progression of the illness, which suggests an increased rate of underweight. However, few studies have addressed underweight in early de novo population. This study aimed to examine the prevalence, risk factors, and clinical correlations of underweight in Chinese newly diagnosed and drug-naïve patients with PD.

Methods

A total of 245 inpatients with newly diagnosed PD and 213 age-, sex-, and education-matched healthy controls were enrolled in Ningbo. BMI, demographics, supine and upright blood pressure, Montreal Cognitive Assessment (MoCA), Hamilton Anxiety Scale (HAMA), Hamilton Depression Scale (HAMD) together with fasting blood glucose, low-density lipoprotein, total cholesterol, uric acid (UA), and homocysteine were collected in all subjects. Hoehn and Yahr (HY) rating and Unified Parkinson’s Disease Rating Scale (UPDRS) motor scores were also measured in patients.

Results

Overall, 35 (14.3%) patients were underweight and 14 (6.6%) controls were underweight. Binary regression analyses showed that low MoCA (p = 0.035), ΔSBP and ΔDBP values (both p < 0.001) were risk factors for underweight. Furthermore, correlation analysis indicated that BMI was associated with HY grade, UPDRS motor, HAMA, HAMD, MoCA, ΔSBP, ΔDBP, and UA values, stepwise multiple regression revealed significant correlations between BMI and ΔSBP (p < 0.001), ΔDBP (p = 0.001), MoCA (p = 0.002), UPDRS motor (p = 0.005), and HAMD scores (p = 0.014).

Conclusions

Our study showed that the prevalence of underweight was significantly higher in Chinese newly diagnosed and drug-naïve patients with PD than in the healthy population, and several clinical variables were risk factors for underweight.
Literature
1.
Uc EY, Struck LK, Rodnitzky RL, Zimmerman B, Dobson J, Evans WJ (2006) Predictors of weight loss in Parkinson;s disease. Mov Disord 21:930–936CrossRef
2.
Wills AM, Perez A, Wang J, Su X, Morgan J, Rajan SS et al (2016) Association between change in body mass index, unified Parkinson’s Disease Rating Scale Scores, and Survival Among Persons With Parkinson Disease: Secondary Analysis of Longitudinal Data From NINDS Exploratory Trials in Parkinson Disease Long-term Study 1. JAMA Neurol 73:321–328CrossRef
3.
van der Marck MA, Dicke HC, Uc EY, Kentin ZH, Borm GF, Bloem BR et al (2012) Body mass index in Parkinson’s disease: a meta-analysis. Parkinsonism Relat Disord 18:263–267CrossRef
4.
Chen H, Zhang SM, Hernan MA, Willett WC, Ascherio A (2003) Weight loss in Parkinson’s disease. Ann Neurol 53:676–679CrossRef
5.
Beyer PL, Palarino MY, Michalek D, Busenbark K, Koller WC (1995) Weight change and body composition in patients with Parkinson’s disease. J Am Diet Assoc 95:979–983CrossRef
6.
Logroscino G, Sesso HD, Paffenbarger RS Jr, Lee IM (2007) Body mass index and risk of Parkinson’s disease: a prospective cohort study. Am J Epidemiol 166:1186–1190CrossRef
7.
Umehara T, Nakahara A, Matsuno H, Toyoda C, Oka H (2017) Body weight and dysautonomia in early Parkinson’s disease. Acta Neurol Scand 135:560–567CrossRef
8.
Postuma RB, Berg D, Stern M, Poewe W, Olanow CW, Oertel W et al (2015) MDS clinical diagnostic criteria for Parkinson’s disease. Mov Disord 30:1591–1601CrossRef
9.
Nasreddine ZS, Phillips NA, Bedirian V, Charbonneau S, Whitehead V, Collin I et al (2005) The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc 53:695–699CrossRef
10.
Hamilton M (1959) The assessment of anxiety states by rating. Br J Med Psychol 32:50–55CrossRef
11.
Hamilton M (1960) A rating scale for depression. J Neurol Neurosurg Psychiatry 23:56–62CrossRef
12.
Fereshtehnejad SM, Lokk J (2014) Orthostatic hypotension in patients with Parkinson’s disease and atypical parkinsonism. Park Dis 2014:475854
13.
Consensus statement on the definition of orthostatic hypotension, pure autonomic failure, and multiple system atrophy (1996) The Consensus Committee of the American Autonomic Society and the American Academy of Neurology. Neurology. 46:1470CrossRef
14.
Sforza M, Assogna F, Rinaldi D, Sette G, Tagliente S, Pontieri FE (2018) Orthostatic hypotension acutely impairs executive functions in Parkinson’s disease. Neurol Sci 39:1459–1462CrossRef
15.
Li H, Zong XN, Ji CY, Mi J (2010) Body mass index cut-offs for overweight and obesity in Chinese children and adolescents aged 2 - 18 years. Zhonghua Liu Xing Bing Xue Za Zhi 31:616–620PubMed
16.
Ma K, Xiong N, Shen Y, Han C, Liu L, Zhang G et al (2018) Weight loss and malnutrition in patients with Parkinson’s disease: current knowledge and future prospects. Front Aging Neurosci 10:1CrossRef
17.
Wills AM, Li R, Perez A, Ren X, Boyd J (2017) Predictors of weight loss in early treated Parkinson’s disease from the NET-PD LS-1 cohort. J Neurol 264:1746–1753CrossRef
18.
Seminara RS, Jeet C, Biswas S, Kanwal B, Iftikhar W, Sakibuzzaman M et al (2018) The neurocognitive effects of Ghrelin-induced signaling on the hippocampus: a promising approach to Alzheimer’s disease. Cureus. 10:e3285PubMedPubMedCentral
19.
Fiszer U, Michalowska M, Baranowska B, Wolinska-Witort E, Jeske W, Jethon M et al (2010) Leptin and ghrelin concentrations and weight loss in Parkinson’s disease. Acta Neurol Scand 121:230–236CrossRef
20.
Kotagal V, Lineback C, Bohnen NI, Albin RL (2016) Orthostatic hypotension predicts motor decline in early Parkinson disease. Parkinsonism Relat Disord 32:127–129CrossRef
21.
Nakamura T, Suzuki M, Ueda M, Hirayama M, Katsuno M (2017) Lower body mass index is associated with orthostatic hypotension in Parkinson’s disease. J Neurol Sci 372:14–18CrossRef
22.
Nakamura T, Suzuki M, Okada A, Suzuki J, Hasegawa S, Koike H et al (2016) Association of leptin with orthostatic blood pressure changes in Parkinson’s disease. Mov Disord 31:1417–1421CrossRef
23.
Jordan J, Shannon JR, Black BK, Ali Y, Farley M, Costa F et al (2000) The pressor response to water drinking in humans : a sympathetic reflex? Circulation. 101:504–509CrossRef
24.
Jordan J, Shannon JR, Grogan E, Biaggioni I, Robertson D (1999) A potent pressor response elicited by drinking water. Lancet (London, England) 353:723CrossRef
25.
Coimbra S, Brandao Proenca J, Santos-Silva A, Neuparth MJ (2014) Adiponectin, leptin, and chemerin in elderly patients with type 2 diabetes mellitus: a close linkage with obesity and length of the disease. Biomed Res Int 2014:701915CrossRef
26.
Considine RV, Sinha MK, Heiman ML, Kriauciunas A, Stephens TW, Nyce MR et al (1996) Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J Med 334:292–295CrossRef
27.
Van Den Saffele JK, Goemaere S, De Bacquer D, Kaufman JM (1999) Serum leptin levels in healthy ageing men: are decreased serum testosterone and increased adiposity in elderly men the consequence of leptin deficiency? Clin Endocrinol 51:81–88CrossRef
28.
Mochizuki H, Taniguchi A, Nakazato Y, Ishii N, Ebihara Y, Sugiyama T et al (2016) Increased body mass index associated with autonomic dysfunction in Parkinson’s disease. Parkinsonism Relat Disord 24:129–131CrossRef
29.
Balestrino R, Baroncini D, Fichera M, Donofrio CA, Franzin A, Mortini P et al (2017) Weight gain after subthalamic nucleus deep brain stimulation in Parkinson’s disease is influenced by dyskinesias’ reduction and electrodes’ position. Neurol Sci 38:2123–2129CrossRef
30.
Wise RA (2013) Dual roles of dopamine in food and drug seeking: the drive-reward paradox. Biol Psychiatry 73:819–826CrossRef
31.
Pilhatsch M, Kroemer NB, Schneider C, Ebersbach G, Jost WH, Fuchs G et al (2013) Reduced body mass index in Parkinson’s disease: contribution of comorbid depression. J Nerv Ment Dis 201:76–79CrossRef
32.
Wang G, Wan Y, Cheng Q, Xiao Q, Wang Y, Zhang J et al (2010) Malnutrition and associated factors in Chinese patients with Parkinson’s disease: results from a pilot investigation. Parkinsonism Relat Disord 16:119–123CrossRef
33.
Sheard JM, Ash S, Silburn PA, Kerr GK (2011) Prevalence of malnutrition in Parkinson’s disease: a systematic review. Nutr Rev 69:520–532CrossRef
Metadata
Title
Prevalence, risk factors, and clinical correlations of underweight in Chinese newly diagnosed and drug-naïve patients with Parkinson’s disease
Authors
Qing Wu
Ming Yu
Jianfei Fu
Meizhen Liu
Publication date
01-03-2021
Publisher
Springer International Publishing
Published in
Neurological Sciences / Issue 3/2021
Print ISSN: 1590-1874
Electronic ISSN: 1590-3478
DOI
https://doi.org/10.1007/s10072-020-04861-0

Other articles of this Issue 3/2021

Neurological Sciences 3/2021 Go to the issue

Letter to the Editor

Marchiafava–Bignami disease–like corpus callosum lesions due to moyamoya disease

Original Article

Low-dose methadone for refractory chronic migraine accompanied by medication-overuse headache: a prospective cohort study

Brief Communication

In the borderland of multifocal motor neuropathy and chronic inflammatory demyelinating polyradiculopathy

Letter to the Editor

Cryptococcal meningoencephalitis in a multiple sclerosis patient after fingolimod discontinuation—a case report

Letter to the Editor

Subacute axial parkinsonism associated with anti-Ri antibodies

Letter to the Editor

Broadening the clinical spectrum of FUS mutations: a case with monomelic amyotrophy with a late progression to amyotrophic lateral sclerosis